Zobrazeno 1 - 10
of 32
pro vyhledávání: '"S. Provent"'
Autor:
F. Selle, J. Gligorov, S. Richard, A. Khalil, I. Alexandre, D. Avenin, S. Provent, D.G. Soares, J.P. Lotz
Publikováno v:
Brazilian Journal of Medical and Biological Research, Vol 48, Iss 1, Pp 13-24 (2015)
Germ cell tumors present contrasting biological and molecular features compared to many solid tumors, which may partially explain their unusual sensitivity to chemotherapy. Reduced DNA repair capacity and enhanced induction of apoptosis appear to be
Externí odkaz:
https://doaj.org/article/bedb7f76644a4490b68613410b7db6de
Autor:
F. Selle, J. Gligorov, S. Richard, A. Khalil, I. Alexandre, D. Avenin, S. Provent, D.G. Soares, J.P. Lotz
Publikováno v:
Brazilian Journal of Medical and Biological Research, Vol 48, Iss 1, Pp 13-24 (2014)
Germ cell tumors present contrasting biological and molecular features compared to many solid tumors, which may partially explain their unusual sensitivity to chemotherapy. Reduced DNA repair capacity and enhanced induction of apoptosis appear to be
Externí odkaz:
https://doaj.org/article/633c09368e4c4fe69695f086bd903ed1
Autor:
F, Dimitriou, K, Namikawa, I L M, Reijers, E I, Buchbinder, J A, Soon, A, Zaremba, P, Teterycz, M J, Mooradian, E, Armstrong, Y, Nakamura, M G, Vitale, L E, Tran, X, Bai, C, Allayous, S, Provent-Roy, A, Indini, P, Bhave, M, Farid, K C, Kähler, I, Mehmi, V, Atkinson, O, Klein, C J, Stonesifer, F, Zaman, A, Haydon, R D, Carvajal, O, Hamid, R, Dummer, A, Hauschild, M S, Carlino, M, Mandala, C, Robert, C, Lebbe, J, Guo, D B, Johnson, P A, Ascierto, A N, Shoushtari, R J, Sullivan, B, Cybulska-Stopa, P, Rutkowski, L, Zimmer, S, Sandhu, C U, Blank, S N, Lo, A M, Menzies, G V, Long
Mucosal melanoma (MM) is a rare melanoma subtype with distinct biology and poor prognosis. Data on the efficacy of immune checkpoint inhibitors (ICIs) are limited. We determined the efficacy of ICIs in MM, analyzed by primary site and ethnicity/race.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc56111b83de57d0e398a5cc2f06c3a3
https://www.ncbi.nlm.nih.gov/pubmed/35716907
https://www.ncbi.nlm.nih.gov/pubmed/35716907
Autor:
Joseph Gligorov, Ahmed Khalil, J. P. Lotz, I. Alexandre, D. Avenin, Sandrine Richard, Frédéric Selle, Daniele G. Soares, S. Provent
Publikováno v:
Brazilian Journal of Medical and Biological Research, Vol 48, Iss 1, Pp 13-24 (2014)
Brazilian Journal of Medical and Biological Research, Vol 48, Iss 1, Pp 13-24 (2015)
Joseph Gligorov
Europe PubMed Central
Brazilian Journal of Medical and Biological Research
Brazilian Journal of Medical and Biological Research, Associação Brasileira de Divulgação Científica, 2015, 48 (1), pp.13-24. ⟨10.1590/1414-431X20144214⟩
Brazilian Journal of Medical and Biological Research, 2015, 48 (1), pp.13-24. ⟨10.1590/1414-431X20144214⟩
Brazilian Journal of Medical and Biological Research v.48 n.1 2015
Associação Brasileira de Divulgação Científica (ABDC)
instacron:ABDC
Brazilian Journal of Medical and Biological Research, Volume: 48, Issue: 1, Pages: 13-24, Published: 04 NOV 2014
Brazilian Journal of Medical and Biological Research, Vol 48, Iss 1, Pp 13-24 (2015)
Joseph Gligorov
Europe PubMed Central
Brazilian Journal of Medical and Biological Research
Brazilian Journal of Medical and Biological Research, Associação Brasileira de Divulgação Científica, 2015, 48 (1), pp.13-24. ⟨10.1590/1414-431X20144214⟩
Brazilian Journal of Medical and Biological Research, 2015, 48 (1), pp.13-24. ⟨10.1590/1414-431X20144214⟩
Brazilian Journal of Medical and Biological Research v.48 n.1 2015
Associação Brasileira de Divulgação Científica (ABDC)
instacron:ABDC
Brazilian Journal of Medical and Biological Research, Volume: 48, Issue: 1, Pages: 13-24, Published: 04 NOV 2014
International audience; Germ cell tumors present contrasting biological and molecular features compared to many solid tumors, which may partially explain their unusual sensitivity to chemotherapy. Reduced DNA repair capacity and enhanced induction of
Autor:
Frédéric Selle, J. P. Lotz, N. Baste-Rotllan, Sandrine Richard, Joseph Gligorov, Daniele G. Soares, D. Avenin, S. Provent, A. Khalil
Publikováno v:
Oncologie. 16:291-299
Le traitement de premiere ligne pour les tumeurs trophoblastiques gestationnelles (TTG) a haut risque consiste en une polychimiotherapie a base de methotrexate, le protocole EMA/CO. Les recommandations francaises preconisent l’utilisation d’un pr
Autor:
J.-M. Miclea, Patrice Viens, J. Geneve, S. Provent, Catherine Lhommé, F. Viret, Joseph Gligorov, G. Lefevre, Jean-Pierre Lotz, B. Gosse, Vincent Ribrag, C. Cailliot, A. Goetschel, François Lokiec, Frédéric Selle, C. Dosquet, Michel Fabbro, Patricia Pautier
Publikováno v:
Bone Marrow Transplantation. 37:669-675
Topotecan has demonstrated activity in ovarian carcinomas. In order to increase the tumour response rate and to define the maximum tolerated dose (MTD) of topotecan, we decided to develop a high-dose phase I regimen supported by stem cell support. Hi
Autor:
Houry S, C. Louvet, F. Maindrault-Goebel, François Paye, Brice Gayet, A. de Gramont, Olivier Rosmorduc, D. Avenin, Frédéric Selle, Laurent Hannoun, Christophe Tournigand, S. Provent, Thierry André, J. P. Lotz
Publikováno v:
Annals of Oncology. 15:1339-1343
Since gemcitabine-oxaliplatin (GEMOX) has been used in pancreatic adenocarcinoma, we studied its activity and tolerability in advanced biliary tract adenocarcinoma (ABTA).Consecutive adult patients with confirmed ABTA were recruited from four centers
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
P. Biron, Frédéric Selle, R. Delva, M. Gaulet, E. Horn, A. Caty, Joseph Gligorov, I. Brindel, L. Geoffrois, I. Temby, Jacques-Olivier Bay, Jean-Michel Miclea, Daniele G. Soares, Gwenaelle Gravis, G. Roubaud, T. de Revel, Binh Bui, Karim Fizazi, S. Wittnebel, S. Provent, Jean-Pierre Lotz, Aude Flechon, Coraline Dubot
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 25(9)
Background High-dose chemotherapy (HDCT) is an effective salvage treatment of germ-cell tumors (GCTs) patients. In the first salvage setting, 30%–70% of patients may achieve durable remissions. Even when HDCT is administered as subsequent salvage t
Autor:
M. Gaulet, G. Gravis-Mescam, P. Biron, Aude Flechon, Coraline Dubot, Remy Delva, Frédéric Selle, Binh Bui, J.M. Miclea, T. de Revel, A. Caty, E. Horn, D. Burcoveanu, Joseph Gligorov, I. Temby, J.-P. Lotz, J. Khalil, Jacques-Olivier Bay, Karim Fizazi, S. Provent, I. Brindel
Publikováno v:
Annals of Oncology. 23:ix260
Background High-dose chemotherapy (HDCT) has been shown to circumvent resistance in poor-prognosis germ cell tumors (GCT), mainly for patients whose relapses occur more than 4 weeks after cisplatin-based CT. Patients and methods This multicentric pha